Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer
Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy...
Saved in:
| Published in | Cancers Vol. 11; no. 8; p. 1154 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
12.08.2019
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC. |
|---|---|
| AbstractList | Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC. Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC.Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC. |
| Author | Lee, Kyungmin Oh, Chan Kim, Hyun Jin Kang, Yea Eun Shong, Minho Koo, Bon Seok Yi, Hyon-Seung Kim, Jung Tae Jung, Seung-Nam Ku, Bon Jeong Won, Ho-Ryun Chang, Jae Won Lim, Mi Ae Liu, Lihua |
| AuthorAffiliation | 2 Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Korea 3 Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon 35015, Korea 1 Department of Endocrinology and Metabolism, Chungnam National University College of Medicine, Daejeon 35015, Korea |
| AuthorAffiliation_xml | – name: 1 Department of Endocrinology and Metabolism, Chungnam National University College of Medicine, Daejeon 35015, Korea – name: 3 Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon 35015, Korea – name: 2 Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Korea |
| Author_xml | – sequence: 1 givenname: Yea Eun surname: Kang fullname: Kang, Yea Eun – sequence: 2 givenname: Jung Tae surname: Kim fullname: Kim, Jung Tae – sequence: 3 givenname: Mi Ae surname: Lim fullname: Lim, Mi Ae – sequence: 4 givenname: Chan surname: Oh fullname: Oh, Chan – sequence: 5 givenname: Lihua surname: Liu fullname: Liu, Lihua – sequence: 6 givenname: Seung-Nam surname: Jung fullname: Jung, Seung-Nam – sequence: 7 givenname: Ho-Ryun surname: Won fullname: Won, Ho-Ryun – sequence: 8 givenname: Kyungmin surname: Lee fullname: Lee, Kyungmin – sequence: 9 givenname: Jae Won surname: Chang fullname: Chang, Jae Won – sequence: 10 givenname: Hyon-Seung orcidid: 0000-0002-3767-1954 surname: Yi fullname: Yi, Hyon-Seung – sequence: 11 givenname: Hyun Jin orcidid: 0000-0002-6760-4963 surname: Kim fullname: Kim, Hyun Jin – sequence: 12 givenname: Bon Jeong orcidid: 0000-0002-3414-8949 surname: Ku fullname: Ku, Bon Jeong – sequence: 13 givenname: Minho surname: Shong fullname: Shong, Minho – sequence: 14 givenname: Bon Seok orcidid: 0000-0002-5928-0006 surname: Koo fullname: Koo, Bon Seok |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31408968$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUtPJCEUhclEo466np0hcTObVh4FNBuTTmdaTUxmo2ukqFvdmGpQoDT-exlf0U6GzSXwnZMD5yfaCjEAQr8oOeFck1Nng4OUKSVTSkXzA-0xothESt1sfdnvosOc70hdnFMl1Q7a5bQhUy2ne-h2lnN03hYfA26hPAEEPPfJjUM9C0u88G2K7WBzwecpPpUVXlhXYsKMYhs6PFsuE-TsHyHUgX3A16vnFH2H56_xDtB2b4cMh-9zH90s_lzPLyZXf88v57OriWsYLRPeukZwoaHphe6pFa4TICxvOkeV5YRPu74l2koAzTgVVmkhBQD0TPeyd3wfnb353o_tGjoHoSQ7mPvk1zY9m2i9-X4T_Mos46ORilHBVTX4_W6Q4sMIuZi1zw6GwQaIYzaMKc6IlFxU9HgDvYtjCvV5holGCcaIJpU6-proM8rH51dAvAEuxZwT9Mb58tpEDegHQ4n517PZ6LnqTjd0H9b_U7wAJbmtAg |
| CitedBy_id | crossref_primary_10_3389_fendo_2021_795116 crossref_primary_10_1038_s41419_021_03588_w crossref_primary_10_1089_thy_2020_0034 crossref_primary_10_61186_nsft_19_2_1 crossref_primary_10_3390_cells10092418 crossref_primary_10_1080_01635581_2022_2118322 crossref_primary_10_1038_s41598_024_79341_y crossref_primary_10_3389_fonc_2021_727984 crossref_primary_10_1111_liv_15100 crossref_primary_10_3390_ijms23073959 crossref_primary_10_3390_diagnostics10060414 crossref_primary_10_1016_j_lfs_2020_118875 crossref_primary_10_3390_cancers14174172 crossref_primary_10_1016_j_yexcr_2021_112661 crossref_primary_10_1177_1535370220920558 crossref_primary_10_1016_j_jhepr_2025_101364 crossref_primary_10_1002_path_5997 crossref_primary_10_3389_fendo_2020_00566 crossref_primary_10_3390_metabo14100565 crossref_primary_10_2217_fon_2019_0780 crossref_primary_10_1016_j_cmet_2024_01_005 crossref_primary_10_1038_s41419_023_06386_8 crossref_primary_10_1186_s12964_024_02003_z crossref_primary_10_1016_j_jhepr_2024_101126 crossref_primary_10_3390_cancers15102863 |
| Cites_doi | 10.1016/j.cmet.2007.05.003 10.1126/scitranslmed.3004690 10.1016/j.metabol.2010.03.018 10.1161/CIRCULATIONAHA.115.015308 10.1006/cyto.1999.0485 10.1371/journal.pone.0098130 10.1155/2012/847108 10.1038/sj.onc.1207331 10.1155/2017/4803156 10.1371/journal.pone.0033870 10.2337/db08-1775 10.1038/nrc2780 10.1038/nrd2792 10.2337/db14-0595 10.1371/journal.pone.0018398 10.1158/1055-9965.EPI-10-1220 10.1172/JCI23606 10.1111/j.1532-5415.2011.03879.x 10.1124/mol.108.049544 10.1158/1078-0432.CCR-07-5270 10.1158/0008-5472.CAN-09-4479 10.1186/1743-7075-9-94 10.1016/j.cyto.2018.02.013 10.1371/journal.pone.0051357 10.1038/srep33953 10.1186/1471-230X-13-67 10.1016/S0167-4781(00)00067-1 10.1093/annonc/mdt419 10.1158/1538-7445.AM2015-1577 10.1016/S0002-9440(10)61177-7 10.1177/030006051204000601 10.1038/nrc.2017.8 10.1002/hep.27060 10.1093/hmg/ddq310 10.1016/j.cmet.2013.08.005 10.1158/2159-8290.CD-12-0362 10.2337/db09-0713 10.1158/0008-5472.CAN-07-2325 10.1074/jbc.M110.215889 10.1507/endocrj.45.35 10.1038/383787a0 10.1038/srep28503 10.1371/journal.pone.0148252 10.1016/j.cmet.2016.12.004 10.1016/j.cmet.2007.05.002 10.1016/j.febslet.2008.10.021 10.3904/kjim.2016.420 10.1016/j.ccr.2007.11.004 10.1042/BJ20101603 10.1016/j.biochi.2012.10.019 10.1056/NEJMoa1406470 10.1038/nm.3014 10.1210/en.2004-1134 10.1016/j.mce.2008.10.052 10.1016/S1474-4422(11)70155-7 10.1016/j.molmet.2012.08.007 10.1210/jc.2010-1071 10.1016/j.bbrc.2007.06.068 10.1124/mol.108.044826 10.1016/j.tem.2014.10.002 10.7554/eLife.00065 |
| ContentType | Journal Article |
| Copyright | 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 by the authors. 2019 |
| Copyright_xml | – notice: 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 by the authors. 2019 |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/cancers11081154 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Biological Science Collection Research Library Biological Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | PMC6721537 31408968 10_3390_cancers11081154 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: National Research Foundation of Korea grantid: 2017R1D1A1B03027820 – fundername: National Research Foundation of Korea grantid: 2016R1D1A1B04932112 – fundername: National Research Foundation of Korea grantid: 2016R1A2A2A05005220 |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c421t-3bc45359e4f59f1a5cd5e5a34dc17a3038dfb09a6ee92315a79565eeef29f6fc3 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Thu Aug 21 13:31:52 EDT 2025 Fri Jul 11 06:11:15 EDT 2025 Fri Jul 25 11:50:50 EDT 2025 Thu Jan 02 22:59:41 EST 2025 Tue Jul 01 01:51:40 EDT 2025 Thu Apr 24 22:58:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | thyroid cancer cell proliferation metastasis FGFR obesity FGF21 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c421t-3bc45359e4f59f1a5cd5e5a34dc17a3038dfb09a6ee92315a79565eeef29f6fc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0002-3414-8949 0000-0002-3767-1954 0000-0002-5928-0006 0000-0002-6760-4963 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers11081154 |
| PMID | 31408968 |
| PQID | 2547522090 |
| PQPubID | 2032421 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6721537 proquest_miscellaneous_2273206635 proquest_journals_2547522090 pubmed_primary_31408968 crossref_citationtrail_10_3390_cancers11081154 crossref_primary_10_3390_cancers11081154 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20190812 |
| PublicationDateYYYYMMDD | 2019-08-12 |
| PublicationDate_xml | – month: 8 year: 2019 text: 20190812 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2019 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Abbas (ref_63) 1996; 383 Nishimura (ref_34) 2000; 1492 Dienstmann (ref_59) 2013; 25 Beenken (ref_7) 2009; 8 Kurosu (ref_13) 2009; 299 ref_56 ref_11 Foltz (ref_10) 2012; 4 Crasto (ref_24) 2012; 60 Kharitonenkov (ref_9) 2005; 115 Babina (ref_58) 2017; 17 Schaap (ref_22) 2013; 95 Ye (ref_37) 2014; 60 Motylewska (ref_51) 2018; 105 Zhang (ref_55) 2012; 1 Badman (ref_14) 2007; 5 ref_65 ref_20 ref_64 Gaich (ref_49) 2013; 18 Hojman (ref_41) 2009; 58 ref_28 Hunt (ref_15) 2007; 360 ref_26 Zhao (ref_44) 2012; 40 Dey (ref_29) 2010; 70 Kim (ref_21) 2013; 19 Koziczak (ref_30) 2004; 23 Markan (ref_46) 2014; 63 Acevedo (ref_5) 2007; 12 Han (ref_25) 2010; 59 Kitahara (ref_45) 2011; 20 Yang (ref_12) 2012; 9 Nicholes (ref_53) 2002; 160 Coate (ref_38) 2017; 25 Mai (ref_16) 2009; 58 ref_35 Yi (ref_43) 2017; 32 Harlid (ref_57) 2017; 2017 Hondares (ref_17) 2011; 286 Lin (ref_36) 2015; 131 Stjepanovic (ref_31) 2014; 8 Izumiya (ref_19) 2008; 582 Wesche (ref_4) 2011; 437 Shingu (ref_33) 1998; 45 Grande (ref_62) 2012; 2012 Chou (ref_27) 2016; 6 Muise (ref_18) 2008; 74 Zheng (ref_32) 2005; 146 Schlumberger (ref_60) 2015; 372 Lee (ref_42) 2011; 96 Pai (ref_52) 2008; 68 Dieci (ref_1) 2013; 3 Inagaki (ref_8) 2007; 5 Tyynismaa (ref_40) 2010; 19 Zhang (ref_2) 2006; 271 Knott (ref_47) 2016; 1 Owen (ref_39) 2015; 26 Xie (ref_54) 1999; 11 Chang (ref_66) 2016; 6 Turner (ref_3) 2010; 10 Marek (ref_6) 2009; 75 ref_48 Suomalainen (ref_23) 2011; 10 Adams (ref_50) 2013; 2 Matsui (ref_61) 2008; 14 |
| References_xml | – volume: 5 start-page: 415 year: 2007 ident: ref_8 article-title: Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21 publication-title: Cell Metabol. doi: 10.1016/j.cmet.2007.05.003 – volume: 4 start-page: ra153 year: 2012 ident: ref_10 article-title: Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3004690 – volume: 59 start-page: 1656 year: 2010 ident: ref_25 article-title: Serum fibroblast growth factor–21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis publication-title: Metabol. Clin. Exp. doi: 10.1016/j.metabol.2010.03.018 – volume: 8 start-page: 129 year: 2014 ident: ref_31 article-title: Multikinase inhibitors in the treatment of thyroid cancer: Specific role of lenvatinib publication-title: Biol. Targets Ther. – volume: 131 start-page: 1861 year: 2015 ident: ref_36 article-title: Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.115.015308 – volume: 11 start-page: 729 year: 1999 ident: ref_54 article-title: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4 publication-title: Cytokine doi: 10.1006/cyto.1999.0485 – ident: ref_28 doi: 10.1371/journal.pone.0098130 – volume: 2012 start-page: 847108 year: 2012 ident: ref_62 article-title: Thyroid cancer: Molecular aspects and new therapeutic strategies publication-title: J. Thyroid Res. doi: 10.1155/2012/847108 – volume: 23 start-page: 3501 year: 2004 ident: ref_30 article-title: Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins publication-title: Oncogene doi: 10.1038/sj.onc.1207331 – volume: 2017 start-page: 4803156 year: 2017 ident: ref_57 article-title: The metabolic syndrome, inflammation, and colorectal cancer risk: An evaluation of large panels of plasma protein markers using repeated, prediagnostic samples publication-title: Mediat. Inflamm. doi: 10.1155/2017/4803156 – ident: ref_11 doi: 10.1371/journal.pone.0033870 – volume: 58 start-page: 1532 year: 2009 ident: ref_16 article-title: Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21 publication-title: Diabetes doi: 10.2337/db08-1775 – ident: ref_65 – volume: 10 start-page: 116 year: 2010 ident: ref_3 article-title: Fibroblast growth factor signalling: From development to cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2780 – volume: 8 start-page: 235 year: 2009 ident: ref_7 article-title: The FGF family: Biology, pathophysiology and therapy publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd2792 – volume: 63 start-page: 4057 year: 2014 ident: ref_46 article-title: Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding publication-title: Diabetes doi: 10.2337/db14-0595 – ident: ref_26 doi: 10.1371/journal.pone.0018398 – volume: 20 start-page: 464 year: 2011 ident: ref_45 article-title: Obesity and thyroid cancer risk among US men and women: A pooled analysis of five prospective studies publication-title: Cancer Epidemiol. Prev. Biomark doi: 10.1158/1055-9965.EPI-10-1220 – volume: 115 start-page: 1627 year: 2005 ident: ref_9 article-title: FGF-21 as a novel metabolic regulator publication-title: J. Clin. Investig. doi: 10.1172/JCI23606 – volume: 60 start-page: 792 year: 2012 ident: ref_24 article-title: Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults publication-title: J. Am. Geriatr. Soc. doi: 10.1111/j.1532-5415.2011.03879.x – volume: 75 start-page: 196 year: 2009 ident: ref_6 article-title: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells publication-title: Mol. Pharmacol. doi: 10.1124/mol.108.049544 – volume: 14 start-page: 5459 year: 2008 ident: ref_61 article-title: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5270 – volume: 70 start-page: 4151 year: 2010 ident: ref_29 article-title: Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-4479 – volume: 9 start-page: 94 year: 2012 ident: ref_12 article-title: Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress publication-title: Nutr. Metabol. doi: 10.1186/1743-7075-9-94 – volume: 105 start-page: 32 year: 2018 ident: ref_51 article-title: Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer publication-title: Cytokine doi: 10.1016/j.cyto.2018.02.013 – ident: ref_56 doi: 10.1371/journal.pone.0051357 – volume: 6 start-page: 33953 year: 2016 ident: ref_27 article-title: Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction publication-title: Sci. Rep. doi: 10.1038/srep33953 – ident: ref_20 doi: 10.1186/1471-230X-13-67 – volume: 1492 start-page: 203 year: 2000 ident: ref_34 article-title: Identification of a novel FGF, FGF-21, preferentially expressed in the liver1 publication-title: Biochim. Biophys. Acta (BBA) Gene Struct. Expr. doi: 10.1016/S0167-4781(00)00067-1 – volume: 25 start-page: 552 year: 2013 ident: ref_59 article-title: Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt419 – ident: ref_48 doi: 10.1158/1538-7445.AM2015-1577 – volume: 160 start-page: 2295 year: 2002 ident: ref_53 article-title: A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice publication-title: Am. J. Pathol. doi: 10.1016/S0002-9440(10)61177-7 – volume: 40 start-page: 2041 year: 2012 ident: ref_44 article-title: Overweight, obesity and thyroid cancer risk: A meta-analysis of cohort studies publication-title: J. Int. Med. Res. doi: 10.1177/030006051204000601 – volume: 17 start-page: 318 year: 2017 ident: ref_58 article-title: Advances and challenges in targeting FGFR signalling in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.8 – volume: 60 start-page: 977 year: 2014 ident: ref_37 article-title: Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice publication-title: Hepatology doi: 10.1002/hep.27060 – volume: 19 start-page: 3948 year: 2010 ident: ref_40 article-title: Mitochondrial myopathy induces a starvation-like response publication-title: Hum. Mol. Genet. doi: 10.1093/hmg/ddq310 – volume: 18 start-page: 333 year: 2013 ident: ref_49 article-title: The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes publication-title: Cell Metabol. doi: 10.1016/j.cmet.2013.08.005 – volume: 3 start-page: 264 year: 2013 ident: ref_1 article-title: Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0362 – volume: 58 start-page: 2797 year: 2009 ident: ref_41 article-title: Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia publication-title: Diabetes doi: 10.2337/db09-0713 – volume: 68 start-page: 5086 year: 2008 ident: ref_52 article-title: Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating β-catenin signaling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-2325 – volume: 271 start-page: 15292 year: 2006 ident: ref_2 article-title: Receptor specificity of the fibroblast growth factor family, part II publication-title: J. Biol. Chem. – volume: 286 start-page: 12983 year: 2011 ident: ref_17 article-title: Thermogenic activation induces FGF21 expression and release in brown adipose tissue publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110.215889 – volume: 45 start-page: 35 year: 1998 ident: ref_33 article-title: Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases publication-title: Endocr. J. doi: 10.1507/endocrj.45.35 – volume: 383 start-page: 787 year: 1996 ident: ref_63 article-title: Functional diversity of helper T lymphocytes publication-title: Nature doi: 10.1038/383787a0 – volume: 6 start-page: 28503 year: 2016 ident: ref_66 article-title: Carboxyl-terminal modulator protein positively acts as an oncogenic driver in head and neck squamous cell carcinoma via regulating Akt phosphorylation publication-title: Sci. Rep. doi: 10.1038/srep28503 – ident: ref_35 doi: 10.1371/journal.pone.0148252 – volume: 25 start-page: 472 year: 2017 ident: ref_38 article-title: FGF21 is an exocrine pancreas secretagogue publication-title: Cell Metabol. doi: 10.1016/j.cmet.2016.12.004 – volume: 5 start-page: 426 year: 2007 ident: ref_14 article-title: Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states publication-title: Cell Metabol. doi: 10.1016/j.cmet.2007.05.002 – volume: 582 start-page: 3805 year: 2008 ident: ref_19 article-title: FGF21 is an Akt-regulated myokine publication-title: FEBS Lett. doi: 10.1016/j.febslet.2008.10.021 – volume: 32 start-page: 780 year: 2017 ident: ref_43 article-title: Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer publication-title: Korean J. Internal Med. doi: 10.3904/kjim.2016.420 – volume: 12 start-page: 559 year: 2007 ident: ref_5 article-title: Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition publication-title: Cancer Cell doi: 10.1016/j.ccr.2007.11.004 – volume: 437 start-page: 199 year: 2011 ident: ref_4 article-title: Fibroblast growth factors and their receptors in cancer publication-title: Biochem. J. doi: 10.1042/BJ20101603 – volume: 95 start-page: 692 year: 2013 ident: ref_22 article-title: Fibroblast growth factor 21 is induced by endoplasmic reticulum stress publication-title: Biochimie doi: 10.1016/j.biochi.2012.10.019 – volume: 372 start-page: 621 year: 2015 ident: ref_60 article-title: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer publication-title: New Engl. J. Med. doi: 10.1056/NEJMoa1406470 – volume: 1 start-page: 015 year: 2016 ident: ref_47 article-title: Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer publication-title: J. Mol. Biomark. Diagn. – volume: 19 start-page: 83 year: 2013 ident: ref_21 article-title: Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine publication-title: Nat. Med. doi: 10.1038/nm.3014 – volume: 146 start-page: 1145 year: 2005 ident: ref_32 article-title: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma publication-title: Endocrinology doi: 10.1210/en.2004-1134 – volume: 299 start-page: 72 year: 2009 ident: ref_13 article-title: The Klotho gene family as a regulator of endocrine fibroblast growth factors publication-title: Mol. Cell. Endocrinol. doi: 10.1016/j.mce.2008.10.052 – volume: 10 start-page: 806 year: 2011 ident: ref_23 article-title: FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: A diagnostic study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(11)70155-7 – ident: ref_64 – volume: 2 start-page: 31 year: 2013 ident: ref_50 article-title: The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue publication-title: Mol. Metabol. doi: 10.1016/j.molmet.2012.08.007 – volume: 96 start-page: E19 year: 2011 ident: ref_42 article-title: Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: A clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E publication-title: J. Clin. Endocrinol. Metabol. doi: 10.1210/jc.2010-1071 – volume: 360 start-page: 437 year: 2007 ident: ref_15 article-title: PPARα is a key regulator of hepatic FGF21 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2007.06.068 – volume: 74 start-page: 403 year: 2008 ident: ref_18 article-title: Adipose fibroblast growth factor 21 is up-regulated by PPARγ and altered metabolic states publication-title: Mol. Pharmacol. doi: 10.1124/mol.108.044826 – volume: 26 start-page: 22 year: 2015 ident: ref_39 article-title: Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21 publication-title: Trends Endocrinol. Metabol. doi: 10.1016/j.tem.2014.10.002 – volume: 1 start-page: e00065 year: 2012 ident: ref_55 article-title: The starvation hormone, fibroblast growth factor-21, extends lifespan in mice publication-title: Elife doi: 10.7554/eLife.00065 |
| SSID | ssj0000331767 |
| Score | 2.3587575 |
| Snippet | Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1154 |
| SubjectTerms | Biomarkers Body mass index Cell viability Cholesterol Energy metabolism Enzyme inhibitors Fibroblast growth factor receptors Fibroblasts Glucose Glucose metabolism Growth factors Homeostasis Kinases Klotho protein Lipid metabolism Liver diseases Mesenchyme Metabolism Metastasis Papillary thyroid cancer Protein expression Protein-tyrosine kinase Serum levels Thyroid cancer Tumorigenesis Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED9trYT2gjY-RjaGjMQDLwHHjpP4aWIVpZoEQohKfQuO7dBKKIE2POy_3zl1A2Uaz3a-7nx3v9_ZuQM4SrjGoFTQkDHLwlgZiTanojCNYyURsCNKcD8KX14lo3H8eyImPuG28McqVz6xddSm1i5HfopEJkWsQCX9-fgUuq5RbnfVt9D4CH10wVnWg_6v86vrmy7LQjnGxyRd1vThyO9PtRPmfOFOv7tKNOvh6B-M-fao5KvYM_wMmx40krOllr_AB1ttwcal3xbfhrtXQib-5BUZzOa67c1V3ZMhkuK6QKDckAvk3c2UDNs-O4RFRFWGnN23tNt7PjKryO30z7yeGTJoP2QHxsPz28Eo9K0TQh2zqAl5oWPBhbRxKWQZKaGNsELx2KBqFIatzJQFlSqx1iE8oVLkScJaWzJZJqXmu9Cr6sruARFWU20yxBVouoxmqqR4D0PdFo1zpQGcrCSYa19X3LW3eMiRXziR529EHsBxd8HjsqTG_6fur1SSe9ta5C8rIYDDbhitwm11qMrWzzgHURlr0VQAX5ca7J7FkVNmMskCSNd0201wFbfXR6rZtK28nSBfFjz99v5rfYdPCKukyzxHbB96zfzZ_kDo0hQHfn3-Bavx8KI priority: 102 providerName: ProQuest |
| Title | Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31408968 https://www.proquest.com/docview/2547522090 https://www.proquest.com/docview/2273206635 https://pubmed.ncbi.nlm.nih.gov/PMC6721537 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-wwEB68wMEX8XY89bJE8MGXetI0aZsHEV1cRVgRcWHfetI0dReke6wV9N87yXZX1wv4nDShM5nM9zXpfAD7UagxKWXUZ8wwn6tcYsypwI85VxIBO6IE-6Nw9yq66PHLvui_yQE1Bnz8ktpZPaledX_4_PByjAF_ZBknUva_2tqnerQX2m1xmXlYxLQUWzmDboP13bYcYqp0irKMxsyPIsnHpX6-GmM2S32Cnh9vUL5LSZ0VWG6wJDkZO38V5ky5Br-6zWn5Ovx7Z3vSXMgi7WGlnWRXeUc6yJVHGeLnmpwjHa8HpOPkdwgLiCpzcnLn2HizIZJhSW4HL9VomJO2e5EN6HXObtsXfqOo4GvOgtoPM81FKKThhZBFoITOhREq5Dl6TGE2S_Iio1JFxljgJ1SM9EkYYwomi6jQ4W9YKEel-QNEGE11niDcwIhmNFEFxTFyak9u7A7rweHEgqluyo1b1Yv7FGmHNXn6weQeHEwf-D-utPF9152JS9LJikmR6cYIJqmkHuxNmzFY7AmIKs3oCfsgWGMOZHmwOfbgdK4QqWYio8SDeMa30w62EPdsSzkcuILcEdJoEcZbP5h3G5YQckn7VTpgO7BQV09mF2FNnbVg8fTs6vqmBfPn_aDlFu8rldH5jA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG9SChgJJC6hjh0n8QGhsnTZ0u4Koa3UW-rYTncllLS7qVD_FL-RcV50i-DWcxzH8Xhmvs9jzwC8ibhGp5RRnzHL_FAZiTqnAj8OQyURsCNKcBeFJ9NofBR-PRbHG_CruwvjjlV2NrE21KbUbo98B4lMjFiBSvrx7Nx3VaNcdLUrodEsiwN7-RMp2-rD_meU71vGRnuz4dhvqwr4OmRB5fNMh4ILacNcyDxQQhthheKhwVErtOiJyTMqVWStAz9CxUghhLU2ZzKPcs2x31uwGfKIsgFsftqbfvve7-pQjv44ipscQpxLuqOd8JYrd9reZb5Zd39_YdrrRzOv-LrRfbjXglSy26yqB7Bhi4dwe9KG4R_ByRWhkvakFxkulrquBVackhGS8DJDYF6RL8jzqzkZ1XV9CAuIKgzZPa1pfmtpyaIgs_nlslwYMqx_5DEc3cikPoFBURb2GRBhNdUmQRyDpoLRROUU-zDUhYSc6fbgfTeDqW7zmLtyGj9S5DNuytNrU-7Bu_6FsyaFx7-bbnciSVtdXqV_Vp4Hr_vHqIUutKIKW15gG0SBrEZvHjxtJNh_iyOHTWSUeBCvybZv4DJ8rz8pFvM603eE_FzweOv_w3oFd8azyWF6uD89eA53EdJJt-sdsG0YVMsL-wJhU5W9bNcqgZObVo_fbTUukA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrVRxQbybUsBIIHEJdew4jwNCZdvQUrqqUCv1ljq2010JJe1uKtS_xq9jnDihWwS3nu04tscz_j57PAPwNuIKN6WC-owZ5odSp6hzMvDjMJQpAnZECfah8OEk2jsJv56K0xX41b-FsW6VvU1sDbWulT0j30IiEyNWoCndKp1bxNFO9uni0rcZpOxNa59Oo1siB-b6J9K3xcf9HZT1O8ay3ePxnu8yDPgqZEHj80KFgovUhKVIy0AKpYURkocaRyDRuie6LGgqI2MsEBIyRjohjDElS8uoVBzbvQersWVFI1j9vDs5-j6c8FCOe3MUd_GEOMeOKyvI-cJ63tsoOMtb4V_49rab5o19L3sIDxxgJdvdCnsEK6Z6DGuH7kr-CZzdEDBxXl9kPJurNi9YdU4yJOR1gSC9IV-Q8zdTkrU5fggLiKw02T5vKb-zumRWkePp9byeaTJuB_IUTu5kUp_BqKorsw5EGEWVThDToNlgNJElxTY0tddD1ox78KGfwVy5mOY2tcaPHLmNnfL81pR78H744KIL5_Hvqpu9SHKn14v8zyr04M1QjBppr1lkZeorrIOIkLVIzoPnnQSHf3Hks0kaJR7ES7IdKtho38sl1WzaRv2OkKsLHm_8v1uvYQ3VIv-2Pzl4AfcR3aX2ADxgmzBq5lfmJSKopnjlliqBs7vWjt8lvDLF |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+Circulating+Fibroblast+Growth+Factor+21+and+Aggressiveness+in+Thyroid+Cancer&rft.jtitle=Cancers&rft.au=Kang%2C+Yea+Eun&rft.au=Kim%2C+Jung+Tae&rft.au=Lim%2C+Mi+Ae&rft.au=Oh%2C+Chan&rft.date=2019-08-12&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=11&rft.issue=8&rft_id=info:doi/10.3390%2Fcancers11081154&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |